Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Randomised Clinical Trial Repurposing ATRA as a Stromal Targeting Agent in a Novel Drug Combination for Pancreatic Cancer

NCT04241276 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT04241276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04241276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Randomised Clinical Trial Repurposing ATRA as a Stromal Targeting Agent in a Novel Drug Combination for Pancreatic Cancer
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 30, 2020
Completion date
February 28, 2029
Enrollment
170 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer